(Q42175195)

18 October 2017

Quantitative strength testing in ALS clinical trials (English)

1 reference

amyotrophic lateral sclerosis

18 October 2017

1 reference

7

Merit Cudkowicz

1 reference

18 October 2017

Jeremy M Shefner

1

1 reference

18 October 2017

Dawei Liu

2

1 reference

18 October 2017

Melanie L Leitner

3

1 reference

18 October 2017

David Schoenfeld

4

1 reference

18 October 2017

Donald R Johns

5

1 reference

18 October 2017

Toby Ferguson

6

1 reference

18 October 2017

language of work or name

English

0 references

publication date

6 July 2016

1 reference

18 October 2017

1 reference

18 October 2017

87

1 reference

18 October 2017

6

1 reference

18 October 2017

617-624

1 reference

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

18 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Electrical impedance myography as a biomarker to assess ALS progression

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Multipoint incremental motor unit number estimation as an outcome measure in ALS.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Quantitative assessment of neuromuscular deficit in ALS.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

Functional outcome measures as clinical trial endpoints in ALS.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977369

A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis

1 December 2018

1 reference

12 December 2020

Quality of life in ALS is maintained as physical function declines

1 reference

12 December 2020

Predictability of disease progression in amyotrophic lateral sclerosis

1 reference

12 December 2020

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

12 December 2020

10.1212/WNL.0000000000002941

Identifiers

DOI

1 reference

18 October 2017

1 reference

18 October 2017

PubMed publication ID

27385750

1 reference